Free Trial
LON:HLN

Haleon 2/28/2025 Earnings Report

Haleon logo
GBX 338.40 -1.70 (-0.50%)
As of 09/19/2025 11:53 AM Eastern

Haleon EPS Results

Actual EPS
GBX 15.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Haleon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Haleon Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Haleon Earnings Headlines

Haleon (LON:HLN) Earns "Buy" Rating from The Goldman Sachs Group
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
See More Haleon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haleon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haleon and other key companies, straight to your email.

About Haleon

Haleon (LON:HLN) (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

View Haleon Profile

More Earnings Resources from MarketBeat